 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| REGN7257 / Regeneron
Enrollment change, Trial completion date: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=33, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=57 --> 33 | Trial completion date: Jan 2026 --> May 2026
- REGN7257 / Regeneron
Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, in Combination with Costimulatory Blockers Delayed Skin Graft Re... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_3482;
c cytokine-induced signaling, and we tested its ability to suppress allogeneic immune cell responses in a mouse model of skin graft rejection when delivered as a monotherapy and in combination with mycophenolate mofetil (MMF) or T cell costimulatory pathway blockers...c cytokine signaling blockade followed by maintenance immunosuppression using the CTLA4-Ig fusion protein abatacept, significantly improved overall skin graft survival (MST IL2RG+CTLA4 =19.5 [****vs control]) compared to REGN7257 induction only (MST IL2RG =11 [****vs control and combo]) or abatacept maintenance only (MST CTLA4 =10 [*vs control, ****vs combo])...These data provide evidence of ? c cytokines as key drivers of allogeneic immune cell responses during acute transplant rejection, offering a potentially novel strategy for the management of transplant patients.
- || REGN7257 / Regeneron
Trial completion date, Trial primary completion date: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (clinicaltrials.gov) - Jul 3, 2023
P1/2, N=57, Recruiting, Sponsor: Regeneron Pharmaceuticals
c cytokines as key drivers of allogeneic immune cell responses during acute transplant rejection, offering a potentially novel strategy for the management of transplant patients. Trial completion date: Aug 2024 --> Jan 2026 | Trial primary completion date: Aug 2024 --> Jan 2026
- | REGN7257 / Regeneron
Journal: Blocking common γ chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models. (Pubmed Central) - Jan 12, 2023
Our findings indicate that γc cytokines contribute to GVHD and aplastic anemia pathology by promoting these characteristic features. By demonstrating that broad inhibition of γc cytokine signaling with REGN7257 protects from immune-mediated disorders, our data provide evidence of γc cytokines as key drivers of pathogenic T cell responses, offering a potential strategy for the management of T cell-mediated diseases.
- REGN7257 / Regeneron
Evaluation of Common Gamma Chain Cytokine Signaling Blockade with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, on Immune Cell Populations in Monkey and Human (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2078;
Taken together, these pharmacological observations highlight the major role for ?c cytokine signaling in maintenance of lymphocyte populations (i.e. NK-cells and T-cells), but not other immune cell populations, such as granulocytes, platelets and red blood cells. Furthermore, our data highlight the importance of ?c cytokines in driving functions of cynomolgus monkeys and human effector NK and T-cells, opening a potential new route for the management of immune-mediated diseases.
- REGN7257 / Regeneron
Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Inflammatory and Autoimmune Diseases (ENMCC - 260-262) - Nov 4, 2022 - Abstract #ASH2022ASH_1591;
Blockade of ?c cytokine signaling with REGN7257 protected mice against immune cell-mediated pathology in multiple disease models: an EAE model of MS, an allogeneic GVHD model, and a xenogeneic GVHD model that uniquely presents hallmarks of both acute and chronic GVHD as well as immune aplastic anemia. These data provide evidence of ?c cytokines as key drivers of pathogenic immune cell responses, offering a potentially novel strategy for the management of inflammatory and autoimmune diseases, such as GVHD, immune aplastic anemia and MS.
- |||||| REGN7257 / Regeneron
Clinical: Open @MDAndersonNews #ClinicalTrial #2021-0245 REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | PI: Tapan Kadia @TapKadia | NCT04409080 | https://t.co/zAx1ZQ0CU8 #leusm (Twitter) - Oct 20, 2022
P1/2
- REGN7257 / Regeneron
EVALUATION OF COMMON GAMMA CHAIN CYTOKINE SIGNALING BLOCKADE WITH REGN7257, AN INTERLEUKIN 2 RECEPTOR GAMMA (IL2RG) MONOCLONAL ANTIBODY, ON IMMUNE CELL POPULATIONS ACROSS SPECIES () - May 13, 2022 - Abstract #EHA2022EHA_2600;
Conclusion Taken together, these pharmacological observations highlight the major role for γc cytokine signaling in maintenance of lymphocyte populations (i.e. NK cells and T cells) in mouse and CM, but not other immune cell populations (i.e. granulocytes, platelets and red blood cells). Furthermore, our data highlight the importance of γc cytokines in driving functions of CM and human T cells, opening a potential new route for the management of T cell-mediated diseases.
- REGN7257 / Regeneron
BLOCKADE OF COMMON GAMMA CHAIN CYTOKINE SIGNALING WITH REGN7257, AN INTERLEUKIN 2 RECEPTOR GAMMA (IL2RG) MONOCLONAL ANTIBODY, PROTECTED MICE FROM GRAFT-VERSUS-HOST DISEASE AND IMMUNE APLASTIC ANEMIA () - May 13, 2022 - Abstract #EHA2022EHA_2599;
Conclusion Blockade of γc cytokine signaling with REGN7257 protected against T cell-mediated pathology in a xenogeneic GVHD mouse model that uniquely presents hallmarks of both acute and chronic GVHD, with T-cell expansion/infiltration into tissues and liver fibrosis, as well as hallmarks of immune aplastic anemia, with bone marrow aplasia and peripheral cytopenia. These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and immune AA.
- | REGN7257 / Regeneron
Trial completion date, Trial primary completion date: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (clinicaltrials.gov) - Oct 24, 2021
P1/2, N=48, Recruiting, Sponsor: Regeneron Pharmaceuticals
These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and immune AA. Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- REGN7257 / Regeneron
[VIRTUAL] Blockade of Common Gamma Chain Cytokines with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Graft-Versus-Host Disease () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1502;
IL2RG blockade with REGN7257 protected mice from human T cell-mediated disease by impacting multiple features of the pathogenic response, including T-cell expansion and infiltration into tissues as well as pro-inflammatory cytokine release, resulting in improved survival. These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and acquired aplastic anemia.
- REGN7257 / Regeneron
[VIRTUAL] Blockade of Common Gamma Chain Cytokines with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Graft-Versus-Host Disease () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1501;
IL2RG blockade with REGN7257 protected mice from human T cell-mediated disease by impacting multiple features of the pathogenic response, including T-cell expansion and infiltration into tissues as well as pro-inflammatory cytokine release, resulting in improved survival. These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and acquired aplastic anemia.
- REGN7257 / Regeneron
[VIRTUAL] Blockade of Common Gamma Chain Cytokines with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Graft-Versus-Host Disease () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1500;
IL2RG blockade with REGN7257 protected mice from human T cell-mediated disease by impacting multiple features of the pathogenic response, including T-cell expansion and infiltration into tissues as well as pro-inflammatory cytokine release, resulting in improved survival. These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and acquired aplastic anemia.
- REGN7257 / Regeneron
[VIRTUAL] Blockade of Common Gamma Chain Cytokines with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Graft-Versus-Host Disease () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1499;
IL2RG blockade with REGN7257 protected mice from human T cell-mediated disease by impacting multiple features of the pathogenic response, including T-cell expansion and infiltration into tissues as well as pro-inflammatory cytokine release, resulting in improved survival. These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and acquired aplastic anemia.
- REGN7257 / Regeneron
[VIRTUAL] Blockade of Common Gamma Chain Cytokines with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, Protected Mice from Graft-Versus-Host Disease () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1498;
IL2RG blockade with REGN7257 protected mice from human T cell-mediated disease by impacting multiple features of the pathogenic response, including T-cell expansion and infiltration into tissues as well as pro-inflammatory cytokine release, resulting in improved survival. These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and acquired aplastic anemia.
- || REGN7257 / Regeneron
Enrollment open: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (clinicaltrials.gov) - Dec 16, 2020
P1/2, N=48, Recruiting, Sponsor: Regeneron Pharmaceuticals
These data provide evidence of γc cytokines as key drivers of T cell-mediated responses, offering a potentially novel strategy for the management of T cell-mediated diseases, such as GVHD and acquired aplastic anemia. Not yet recruiting --> Recruiting
- || REGN7257 / Regeneron
New P1/2 trial: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (clinicaltrials.gov) - May 31, 2020
P1/2, N=48, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals